Astrazeneca Plc ADR (AZN)

$193.03 +5.87 (3.14%)
Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
DefenseMania
DefenseMania Jul. 3 at 4:12 AM
$GILD $AZN we’re still cheap here at this level
0 · Reply
topstockalerts
topstockalerts Jul. 3 at 12:49 AM
$AZN this strength feels real… not just a quick pop
0 · Reply
Chipwars
Chipwars Jul. 2 at 8:17 PM
$AZN $200 next week
0 · Reply
StreakGeek
StreakGeek Jul. 2 at 5:40 PM
$GWRE $EFX $FROG $AZN meant
0 · Reply
TalkMarkets
TalkMarkets Jul. 2 at 4:25 PM
The FTSE 100 Finish Line - Thursday, July 2 $AZN $CCH $JPM https://talkmarkets.com/article/the-ftse-100-finish-line---thursday-july-2-1783009497
0 · Reply
Chipwars
Chipwars Jul. 2 at 2:41 PM
$AZN For AstraZeneca, the latest approval strengthens its oncology franchise in China, one of its largest global markets, while giving Hutchmed a third approved indication for its homegrown oncology asset, reinforcing the commercialization potential of Chinese-developed targeted cancer medicines.
0 · Reply
Chipwars
Chipwars Jul. 2 at 2:39 PM
$AZN This is big. https://www.chinadaily.com.cn/a/202607/02/WS6a46623da310986e2b463394.html
0 · Reply
Chipwars
Chipwars Jul. 2 at 2:37 PM
$AZN https://www.reuters.com/legal/litigation/astrazeneca-signs-cspc-china-deal-experimental-kidney-disease-drugs-2026-07-02/
0 · Reply
MarketCommanderr
MarketCommanderr Jul. 2 at 2:28 PM
$AZN inks a near $1.8B deal with CSPC for renal disease drugs. Another signal that AZN is still leaning hard into pipeline expansion and pipeline optionality in a high-need area. Bullish for the long game if execution holds.
0 · Reply
MarketPulsee
MarketPulsee Jul. 2 at 1:40 PM
$AZN higher on the Abbisko collaboration. Jointly advancing an IO-TKI combo for NSCLC keeps the pipeline narrative alive and adds optionality in oncology. Market looks to be reading this as strategic, not just incremental.
0 · Reply
Latest News on AZN
AstraZeneca PLC (AZN) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 76/100

2026-07-02T22:19:51.000Z - 1 day ago

AstraZeneca PLC (AZN) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 76/100

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

Thu, 02 Jul 2026 06:16:16 -0400 - 2 days ago

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Therapy

2026-07-02T06:59:06.000Z - 2 days ago

Abbisko Therapeutics Partners with AstraZeneca on Lung Cancer Therapy

Abbisko Therapeutics And AstraZeneca Enter Strategic Collaboration For Lumipodlin

2026-07-02T05:12:59.000Z - 2 days ago

Abbisko Therapeutics And AstraZeneca Enter Strategic Collaboration For Lumipodlin

AstraZeneca, Abbisko Therapeutics enter strategic collaboration

2026-07-02T01:05:08.000Z - 2 days ago

AstraZeneca, Abbisko Therapeutics enter strategic collaboration

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

Wed, 01 Jul 2026 21:00:00 -0400 - 2 days ago

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Tells Investors

2026-07-01T22:07:09.000Z - 2 days ago

AstraZeneca PLC (AZN) Shares Fall 3.0% -- What GF Score of 76 Tells Investors

AstraZeneca (AZN) Faces Competition from Anthropic's New AI in Pharma Research

2026-06-30T18:26:45.000Z - 4 days ago

AstraZeneca (AZN) Faces Competition from Anthropic's New AI in Pharma Research

AstraZeneca (AZN) Secures EU Approval for Enhertu in Cancer Treatment

2026-06-29T10:50:41.000Z - 5 days ago

AstraZeneca (AZN) Secures EU Approval for Enhertu in Cancer Treatment

AstraZeneca announces Enhertu approval in EU for HER2 positive solid tumors

2026-06-29T09:30:37.000Z - 5 days ago

AstraZeneca announces Enhertu approval in EU for HER2 positive solid tumors

AstraZeneca announces results from the MULBERRY Phase III trial

2026-06-28T23:15:06.000Z - 5 days ago

AstraZeneca announces results from the MULBERRY Phase III trial

AstraZeneca (AZN) Receives EU Approval Recommendation for Breast Cancer Treatment

2026-06-26T12:28:05.000Z - 8 days ago

AstraZeneca (AZN) Receives EU Approval Recommendation for Breast Cancer Treatment

AstraZeneca reports Datroway recommended for approval in EU by CHMP

2026-06-26T11:10:59.000Z - 8 days ago

AstraZeneca reports Datroway recommended for approval in EU by CHMP

Daiichi Sankyo: Datroway Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

2026-06-26T11:06:00.000Z - 8 days ago

Daiichi Sankyo: Datroway Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.

Wed, 24 Jun 2026 15:42:00 -0400 - 9 days ago

For decades, the only first treatment for one of the deadliest breast cancers was standard chemotherapy. Now there are two newly approved drugs.

Top FTSE Shares for Beginners to Buy in 2026: AZN, REL and RR.

2026-06-24T15:07:09.000Z - 10 days ago

Top FTSE Shares for Beginners to Buy in 2026: AZN, REL and RR.

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

Wed, 24 Jun 2026 09:00:00 -0400 - 10 days ago

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

AIM Advances Phase 2 DURIPANC Study In Pancreatic Cancer; Expects Topline Data In Q1,2027

2026-06-22T09:44:52.000Z - 12 days ago

AIM Advances Phase 2 DURIPANC Study In Pancreatic Cancer; Expects Topline Data In Q1,2027

The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs

Fri, 19 Jun 2026 07:52:00 -0400 - 15 days ago

The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs

U.S. opens tariff probe targeting Germany's drug pricing policies

Fri, 19 Jun 2026 04:47:04 -0400 - 15 days ago

U.S. opens tariff probe targeting Germany's drug pricing policies

The Healthcare M&A Wave

Wed, 17 Jun 2026 12:30:08 -0400 - 17 days ago

The Healthcare M&A Wave

Ozempic Linked To Lower Risk Of Violence In New Study

Wed, 17 Jun 2026 11:45:12 -0400 - 17 days ago

Ozempic Linked To Lower Risk Of Violence In New Study

The Zacks Analyst Blog Highlights Applied Materials, GE, AstraZeneca, Team and Applied Energetics

2026-06-17T07:36:00.000Z - 17 days ago

The Zacks Analyst Blog Highlights Applied Materials, GE, AstraZeneca, Team and Applied Energetics

Top Stock Reports for Applied Materials, GE & AstraZeneca

2026-06-16T20:28:00.000Z - 17 days ago

Top Stock Reports for Applied Materials, GE & AstraZeneca

AstraZeneca (AZN) Faces Changes in Medicare Drug Price Negotiation Framework

2026-06-15T17:27:01.000Z - 19 days ago

AstraZeneca (AZN) Faces Changes in Medicare Drug Price Negotiation Framework

AstraZeneca (AZN) Receives Priority Review for Ultomiris Treatment Application

2026-06-15T12:25:32.000Z - 19 days ago

AstraZeneca (AZN) Receives Priority Review for Ultomiris Treatment Application

AstraZeneca’s sBLA for Ultomiris granted Priority Review by U.S. FDA

2026-06-15T10:55:08.000Z - 19 days ago

AstraZeneca’s sBLA for Ultomiris granted Priority Review by U.S. FDA

Drugmakers race to find a place in the next wave of obesity drugs

Sat, 13 Jun 2026 08:00:01 -0400 - 21 days ago

Drugmakers race to find a place in the next wave of obesity drugs

AstraZeneca : FDA Approves Truqap Combination For PTEN-Deficient Metastatic Prostate Cancer

2026-06-13T06:43:33.000Z - 21 days ago

AstraZeneca : FDA Approves Truqap Combination For PTEN-Deficient Metastatic Prostate Cancer

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Fri, 12 Jun 2026 18:44:00 -0400 - 21 days ago

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

TRUQAP (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

2026-06-12T22:44:00.000Z - 21 days ago

TRUQAP (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

AstraZeneca (AZN) Gains from New Diagnostic Test Approval

2026-06-12T20:51:18.000Z - 21 days ago

AstraZeneca (AZN) Gains from New Diagnostic Test Approval

AstraZeneca (AZN) Receives FDA Approval for Truqap in Advanced Prostate Cancer

2026-06-12T19:57:28.000Z - 21 days ago

AstraZeneca (AZN) Receives FDA Approval for Truqap in Advanced Prostate Cancer

AstraZeneca (AZN) Secures U.S. Approval for Innovative Prostate Cancer Treatment

2026-06-12T19:27:12.000Z - 21 days ago

AstraZeneca (AZN) Secures U.S. Approval for Innovative Prostate Cancer Treatment

Truqap approved for PTEN-deficient metastatic hormone-sensitive prostate cancer

2026-06-12T18:10:10.000Z - 22 days ago

Truqap approved for PTEN-deficient metastatic hormone-sensitive prostate cancer

Stephen Garbesi and the AI Sales Agent Revolution

2026-06-11T23:24:03.000Z - 22 days ago

Stephen Garbesi and the AI Sales Agent Revolution

BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)

Thu, 11 Jun 2026 02:20:00 -0400 - 23 days ago

BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)

AstraZeneca gets CDSCO approval to sell Enhertu in India for first-line HER2-positive breast cancer treatment

2026-06-11T05:12:34.000Z - 23 days ago

AstraZeneca gets CDSCO approval to sell Enhertu in India for first-line HER2-positive breast cancer treatment

Morning Mail: One Nation’s ‘sloppy’ finances, Trump signals new Iran strikes, who will win the World Cup?

2026-06-10T20:41:17.000Z - 23 days ago

Morning Mail: One Nation’s ‘sloppy’ finances, Trump signals new Iran strikes, who will win the World Cup?

Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?

2026-06-10T15:00:50.000Z - 24 days ago

Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?

GSK steps up cancer fight as new boss Luke Miels signals a change of direction: ALEX BRUMMER

2026-06-09T21:01:02.000Z - 24 days ago

GSK steps up cancer fight as new boss Luke Miels signals a change of direction: ALEX BRUMMER

AstraZeneca's obesity drug shows promise as analysts see upside beyond consensus

Tue, 09 Jun 2026 09:35:18 -0400 - 25 days ago

AstraZeneca's obesity drug shows promise as analysts see upside beyond consensus

AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results

2026-06-08T23:57:22.000Z - 25 days ago

AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results

AstraZeneca Transcript: Investor update

Jun 8, 2026, 7:00 PM EDT - 25 days ago

AstraZeneca Transcript: Investor update

AstraZeneca Slides: Investor update

Jun 8, 2026, 7:00 PM EDT - 25 days ago

AstraZeneca Slides: Investor update

AstraZeneca (AZN) Reports Promising Phase IIb Results for Elecoglipron

2026-06-08T21:53:30.000Z - 25 days ago

AstraZeneca (AZN) Reports Promising Phase IIb Results for Elecoglipron

AstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D

2026-06-08T20:27:14.000Z - 25 days ago

AstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D

AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial

Mon, 08 Jun 2026 16:16:41 -0400 - 25 days ago

AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

2026-06-08T12:33:00.000Z - 26 days ago

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

Top 10 London Stock Exchange Stocks to Consider Buying in 2026 for UK Exposure

2026-06-06T12:27:23.000Z - 4 weeks ago

Top 10 London Stock Exchange Stocks to Consider Buying in 2026 for UK Exposure

AstraZeneca CEO: AI helps us make smarter choices when developing drugs

2026-06-05T23:24:33.000Z - 4 weeks ago

AstraZeneca CEO: AI helps us make smarter choices when developing drugs

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

2026-06-05T23:24:29.000Z - 4 weeks ago

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

Jun 5, 2026, 6:26 PM EDT - 4 weeks ago

AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

Jun 5, 2026, 8:55 AM EDT - 4 weeks ago

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

AstraZeneca announces additional results from Phase III Serena-6 trial

2026-06-02T13:35:12.000Z - 4 weeks ago

AstraZeneca announces additional results from Phase III Serena-6 trial

AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial

2026-06-02T13:19:29.000Z - 4 weeks ago

AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

Jun 2, 2026, 8:00 AM EDT - 4 weeks ago

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

5 Foreign Stocks That Could Beat The S&P 500

Jun 1, 2026, 2:44 PM EDT - 4 weeks ago

5 Foreign Stocks That Could Beat The S&P 500

ASML BHP HSBC

AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi

2026-06-01T12:42:58.000Z - 4 weeks ago

AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

AstraZeneca Transcript: Investor update

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

AstraZeneca Transcript: Investor update

AstraZeneca Slides: Investor update

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

AstraZeneca Slides: Investor update

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

Jun 1, 2026, 5:20 AM EDT - 4 weeks ago

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint

2026-05-29T13:09:01.000Z - 5 weeks ago

AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

May 28, 2026, 9:18 PM EDT - 5 weeks ago

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

US FDA extends review of AstraZeneca's experimental breast cancer pill

May 27, 2026, 2:23 AM EDT - 5 weeks ago

US FDA extends review of AstraZeneca's experimental breast cancer pill

How Big Pharma Is Turning Industrial Heat Into A Strategic Asset

May 26, 2026, 9:41 AM EDT - 5 weeks ago

How Big Pharma Is Turning Industrial Heat Into A Strategic Asset

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

May 22, 2026, 9:30 AM EDT - 6 weeks ago

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

May 22, 2026, 7:00 AM EDT - 6 weeks ago

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

May 22, 2026, 6:45 AM EDT - 6 weeks ago

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug

US Supreme Court rebuffs pharma challenge to Biden-era drug price

May 18, 2026, 9:44 AM EDT - 6 weeks ago

US Supreme Court rebuffs pharma challenge to Biden-era drug price

BMY NVO NVS

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

May 18, 2026, 7:00 AM EDT - 6 weeks ago

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

AstraZeneca Gets U.S. Approval for Hypertension Drug

May 18, 2026, 2:13 AM EDT - 6 weeks ago

AstraZeneca Gets U.S. Approval for Hypertension Drug

AstraZeneca's blood pressure drug wins U.S. approval

May 18, 2026, 2:01 AM EDT - 6 weeks ago

AstraZeneca's blood pressure drug wins U.S. approval

AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

May 14, 2026, 2:59 AM EDT - 7 weeks ago

AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

May 13, 2026, 1:00 AM EDT - 7 weeks ago

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

May 12, 2026, 9:45 AM EDT - 7 weeks ago

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

R

AstraZeneca stock falls after FDA panel votes against new cancer drug

May 1, 2026, 5:51 AM EDT - 2 months ago

AstraZeneca stock falls after FDA panel votes against new cancer drug

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

May 1, 2026, 3:56 AM EDT - 2 months ago

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

May 1, 2026, 3:09 AM EDT - 2 months ago

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

FDA panel votes against backing AstraZeneca's breast cancer drug

Apr 30, 2026, 1:48 PM EDT - 2 months ago

FDA panel votes against backing AstraZeneca's breast cancer drug

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Apr 29, 2026, 7:00 PM EDT - 2 months ago

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

AstraZeneca Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:30 AM EDT - 2 months ago

AstraZeneca Earnings Call Transcript: Q1 2026

AstraZeneca Quarterly report: Q1 2026

Apr 29, 2026, 9:30 AM EDT - 2 months ago

AstraZeneca Quarterly report: Q1 2026

AstraZeneca Slides: Q1 2026

Apr 29, 2026, 9:30 AM EDT - 2 months ago

AstraZeneca Slides: Q1 2026

AstraZeneca to make $405 million investment in Britain, PM Starmer says

Apr 29, 2026, 7:26 AM EDT - 2 months ago

AstraZeneca to make $405 million investment in Britain, PM Starmer says

AstraZeneca Gets Revenue Boost From Cancer Drugs

Apr 29, 2026, 2:27 AM EDT - 2 months ago

AstraZeneca Gets Revenue Boost From Cancer Drugs

AstraZeneca beats profit expectations, keeps annual outlook unchanged

Apr 29, 2026, 2:05 AM EDT - 2 months ago

AstraZeneca beats profit expectations, keeps annual outlook unchanged

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Apr 27, 2026, 7:00 AM EDT - 2 months ago

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Germany risks missing out on new drugs, AstraZeneca CEO tells paper

Apr 21, 2026, 8:50 AM EDT - 2 months ago

Germany risks missing out on new drugs, AstraZeneca CEO tells paper

AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease

Apr 21, 2026, 2:26 AM EDT - 2 months ago

AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Apr 20, 2026, 7:00 AM EDT - 2 months ago

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups

Apr 20, 2026, 2:17 AM EDT - 2 months ago

AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups

Trump policies, China's biotech boom are ending Europe's pharma powerhouse era

Apr 11, 2026, 1:54 AM EDT - 3 months ago

Trump policies, China's biotech boom are ending Europe's pharma powerhouse era

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 3 months ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 3 months ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

NVO ABBV AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 3 months ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 3 months ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

NVO ABBV AMGN BMY MRK

DefenseMania
DefenseMania Jul. 3 at 4:12 AM
$GILD $AZN we’re still cheap here at this level
0 · Reply
topstockalerts
topstockalerts Jul. 3 at 12:49 AM
$AZN this strength feels real… not just a quick pop
0 · Reply
Chipwars
Chipwars Jul. 2 at 8:17 PM
$AZN $200 next week
0 · Reply
StreakGeek
StreakGeek Jul. 2 at 5:40 PM
$GWRE $EFX $FROG $AZN meant
0 · Reply
TalkMarkets
TalkMarkets Jul. 2 at 4:25 PM
The FTSE 100 Finish Line - Thursday, July 2 $AZN $CCH $JPM https://talkmarkets.com/article/the-ftse-100-finish-line---thursday-july-2-1783009497
0 · Reply
Chipwars
Chipwars Jul. 2 at 2:41 PM
$AZN For AstraZeneca, the latest approval strengthens its oncology franchise in China, one of its largest global markets, while giving Hutchmed a third approved indication for its homegrown oncology asset, reinforcing the commercialization potential of Chinese-developed targeted cancer medicines.
0 · Reply
Chipwars
Chipwars Jul. 2 at 2:39 PM
$AZN This is big. https://www.chinadaily.com.cn/a/202607/02/WS6a46623da310986e2b463394.html
0 · Reply
Chipwars
Chipwars Jul. 2 at 2:37 PM
$AZN https://www.reuters.com/legal/litigation/astrazeneca-signs-cspc-china-deal-experimental-kidney-disease-drugs-2026-07-02/
0 · Reply
MarketCommanderr
MarketCommanderr Jul. 2 at 2:28 PM
$AZN inks a near $1.8B deal with CSPC for renal disease drugs. Another signal that AZN is still leaning hard into pipeline expansion and pipeline optionality in a high-need area. Bullish for the long game if execution holds.
0 · Reply
MarketPulsee
MarketPulsee Jul. 2 at 1:40 PM
$AZN higher on the Abbisko collaboration. Jointly advancing an IO-TKI combo for NSCLC keeps the pipeline narrative alive and adds optionality in oncology. Market looks to be reading this as strategic, not just incremental.
0 · Reply
RockyTSTH
RockyTSTH Jul. 2 at 1:28 PM
$AZN AstraZeneca shares are trading higher after the company announced it entered into a strategic collaboration agreement with Abbisko Therapeutics to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer. The company and CSPC Pharmaceutical Group entered into an agreement to use the siRNA drug discovery platform to develop novel small nucleic acid drug candidates.
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 2 at 12:49 PM
$AZN (+2.6% pre) Abbisko and AstraZeneca to trial oral PD-L1 drug with Tagrisso https://ooc.bz/l/106749
0 · Reply
MissNotorious
MissNotorious Jul. 2 at 8:19 AM
$AZN Astrazeneca to Collaborate With Abbisko Therapeutics for Potential Non-Small Cell Lung Cancer Treatment
0 · Reply
p3akyblinder
p3akyblinder Jun. 30 at 9:16 PM
$ABVX Extremely bullish raise and a major show of strength to pharma. Wall Street knows this is for M&A leverage since the commercial team/strategy is already built out. If $LLY or $AZN acquire us now, they get a free 600M in the bank. Congrats longs, the end game is approaching.
0 · Reply
TonyK666
TonyK666 Jun. 30 at 4:56 PM
$AZN is $AZN THE WINNER??? ON $ ABVX?
1 · Reply
p3akyblinder
p3akyblinder Jun. 30 at 3:29 PM
$ABVX Either $LLY or $AZN will buy us for 15-20B imho
0 · Reply
Polip
Polip Jun. 30 at 2:29 PM
$ABVX market is punishing $AZN despite recent approvals because they will have to compete with $LLY to get Abivax
0 · Reply
termalerts
termalerts Jun. 28 at 9:20 PM
ASTRAZENECA'S ALXN1850 TRIAL ACHIEVES POSITIVE RESULTS, FAVORABLE SAFETY, AND KEY BONE HEALTH ENDPOINT $AZN
0 · Reply
Hollywood_1
Hollywood_1 Jun. 27 at 4:55 AM
$AZN MAs reclaimed
0 · Reply
Ron_Burn
Ron_Burn Jun. 26 at 2:42 PM
$AZN smart money accumulating alright, the fall in dollar is causing algos to switch up... Let's see if it presists on Monday
0 · Reply
Chipwars
Chipwars Jun. 24 at 11:08 PM
$AZN https://kalkinemedia.com/uk/stocks/healthcare/astrazenecas-next-chapter-what-is-driving-market-attention
0 · Reply
wwmeinc
wwmeinc Jun. 24 at 2:10 AM
$VKTX $AZN $NVO .....Just punching in a few phrase's on Gemini(free site though)....tonight they have 'offered' up AZN as a good fit for some or all of VKTX.....a chunk off the old VKTX seems more plausible at this stage though...anyways...just picking 'its' database for tidbits/crumbs...glta "The "Fixed-Dose Combo" Obsession: At the 2026 ADA meeting, AstraZeneca's R&D leadership explicitly stated their goal is to combine their oral GLP-1 (elecoglipron) with other mechanisms to maximize muscle-sparing weight loss. By acquiring Viking's amylin pipeline, AZN could build powerful, proprietary internal combinations (GLP-1 + GIP + Amylin) that mimic Novo Nordisk's high-potency CagriSema strategy."
1 · Reply